{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:38:35Z","timestamp":1793893115395,"version":"4.8.0"},"reference-count":14,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    Approximately 30%-50% of patients develop acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (Allo-HCT), representing a major limitation of this treatment. Although corticosteroids remain the standard first-line therapy for aGVHD, up to 50% of patients become steroid-refractory (SR). REACH2 is a phase III study of ruxolitinib versus best available therapy (BAT) in patients age 12 years and older with SR-aGVHD after Allo-HCT. We present the final efficacy and safety outcomes from REACH2 after 24 months of treatment. Cumulative median (range) duration of response was 167 (22-677) days with ruxolitinib and 106 (10-526) days with BAT. Median overall survival and event-free survival were 10.7 and 8.3 months for ruxolitinib, compared with 5.8 and 4.2 months, respectively, with BAT. Median failure-free survival was significantly longer with ruxolitinib than with BAT (4.86\n                    <jats:italic toggle=\"yes\">v<\/jats:italic>\n                    1.02 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001). Similar numbers of nonrelapse mortality events were observed with ruxolitinib and BAT (72\n                    <jats:italic toggle=\"yes\">v<\/jats:italic>\n                    71), and malignancy relapse\/progression events remained low across both groups. Numerically higher chronic GVHD rates were noted with ruxolitinib than with BAT from 12 months; however, 95% confidence intervals overlapped. Safety observations were consistent with the primary analysis results. Ruxolitinib provided efficacy advantages over BAT in patients with SR-aGVHD over 24 months.\n                  <\/jats:p>","DOI":"10.1200\/jco-25-00809","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:00:08Z","timestamp":1760558408000},"page":"3639-3645","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02913261","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":true,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"H\u00f4pital Saint-Antoine, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Universit\u00e9 Sorbonne and INSERM Unit\u00e9 Mixte de Recherche (UMR) 938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-7533","authenticated-orcid":true,"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00e9matologie\u2013Transplantation, H\u00f4pital St Louis, Universit\u00e9 de Paris and INSERM UMR 1342, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":true,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotheraphies, University of Pennsylvania &amp; Penn Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva","family":"Wagner-Drouet","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Or","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Research Center, Hadassah University Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsila","family":"Rovenvald-Zuckerman","sequence":"additional","affiliation":[{"name":"Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem Civriz","family":"Bozdag","sequence":"additional","affiliation":[{"name":"Ankara University Medical Faculty, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":true,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, CHU Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-9969","authenticated-orcid":true,"given":"Giovanni","family":"Grillo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation GOM Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"University Medical Center, Hamburg Eppendorf, Eppendorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":true,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Dresden, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"Division of Stem Cell Transplantation and Cellular Immunotherapy, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-6261","authenticated-orcid":true,"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, ASST degli Spedali Civili di Brescia, Universit\u00e0 degli Studi, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":true,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia Department de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt Ltd, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Stefanelli","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Wilke","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":true,"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center and University Cancer Center Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00342-3"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717741860"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0804-2"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01741-3"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.137"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-812891"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908549116"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2242"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3517"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635"},{"key":"e_1_3_8_14_2","first-page":"2771","article-title":"Prognostic value of blood biomarkers in steroidrefractory or steroid-dependent acute graft-versus host disease: A REACH2 analysis","volume":"141","author":"Soci\u00e9 G","year":"2023","unstructured":"Soci\u00e9 G, Niederwieser D, von Bubnoff N, et al: Prognostic value of blood biomarkers in steroidrefractory or steroid-dependent acute graft-versus host disease: A REACH2 analysis. Blood 141:2771-2779, 2023","journal-title":"Blood"},{"key":"e_1_3_8_15_2","unstructured":"Jakavi: Summary of Product Characteristics (SmPC). 2025"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:59:35Z","timestamp":1764025175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1200\/JCO-25-00809"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00809","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}